ViaNautis.png
ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines
October 28, 2024 08:00 ET | ViaNautis Bio
ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines Multi-year collaboration will use...
ViaNautis.png
ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines
October 28, 2024 03:00 ET | ViaNautis Bio
ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines Multi-year collaboration will use...
ViaNautis.png
ViaNautis Appoints Ray Jupp as Chief Scientific Officer
October 21, 2024 02:00 ET | ViaNautis Bio
ViaNautis Appoints Ray Jupp as Chief Scientific Officer Cambridge, UK 21 October – ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking biotechnology company at the forefront of genetic...
ViaNautis.png
ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer
October 18, 2024 07:00 ET | ViaNautis Bio
ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer Cambridge UK, 18 October 2024 – ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking nanomedicine company at the forefront...
Rapport_Logo_Color_RGB.png
Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
August 08, 2024 07:00 ET | Rapport Therapeutics, Inc.
Rapport Therapeutics announces financial results for Q2 2024 and provides a business update, including progress on its precision neuroscience pipeline
Jeanne Schow, Senior Vice President, Business Development
Avance Clinical Announces Senior Appointment to North American Operations
July 31, 2024 02:45 ET | Avance Clinical
ADELAIDE, Australia and WAKE FOREST, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- Avance Clinical, an award-winning, mid-sized full-service global Contract Research Organization (CRO) for biotech...
Kaerus Logo
Kaerus Bioscience Announces Initiation of Phase 1 Clinical Trial for its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome
July 25, 2024 05:00 ET | Kaerus Bioscience
LONDON, July 25, 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. (www.kaerusbio.com), a clinical-stage biotechnology company focused on developing therapeutics for rare genetic syndromes of...
logo-01 (3) copy - Copy2.jpg
ConSynance Therapeutics Announces U.S. FDA Grants Rare Pediatric Disease Designation to CSTI-500, a Potential First-in-Class Therapy for Prader-Willi Syndrome
July 24, 2024 10:00 ET | ConSynance Therapeutics
FDA awards ConSynance's CSTI-500 Rare Pediatric Disease Designation for innovative Prader-Willi Syndrome treatment.
Rapport_Logo_Color_RGB.png
Rapport Therapeutics Announces Pricing of Initial Public Offering
June 06, 2024 18:54 ET | Rapport Therapeutics, Inc.
BOSTON and SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational...
Stalilcla logo.png
STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant) to treat cocaine use disorder
May 02, 2024 08:01 ET | STALICLA
Geneva, Switzerland, May 2, 2024 – STALICLA SA, a late-stage biotechnology company specializing in precision medicine for brain disorders, announces the First Patient First Visit (FPFV) for the...